Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)Brenzavvy Now Available for Adults with Type 2 Diabetes

TheracosBio has partnered with the Mark Cuban Cost Plus Drug Company to distribute Brenzavvy.

Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 inhibitor, recently received approval for use as an adjunct to diet and exercise to enhance glycemic control in adult type 2 diabetes patients. This significant stride in the diabetes therapy market emanates from the TheracosBio program and is anticipated to lower treatment cost barriers, thereby expanding utilization.

Key Points:

  • Brenzavvy, backed by data from 23 clinical trials involving more than 5,000 adults with type 2 diabetes, is now approved.
  • The drug is administered as a 20mg tablet, once daily in the morning.
  • Renal function and volume status should be assessed before initiating Brenzavvy treatment; it’s not recommended for patients with an eGFR less than 30mL/min/1.732 and contraindicated in dialysis patients.

Additional Points:

  • A 30-day supply of Brenzavvy is priced at $47.85 plus shipping and handling.


  • The launch of Brenzavvy heralds the first phase of TheracosBio’s mission to bring cost-effective novel medications to the US population.

Endocrinology Latest Posts

“The commercialization of Brenzavvy marks the first phase of the TheracosBio program to bring cost-effective novel medications to the US population, expanding markets by reducing barriers to greater utilization.”

Albert R. Collinson, PhD
President and CEO
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form